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Background: Genetic tests for primary immunodeficiency disorders (PIDs) are
expensive, time-consuming, and not easily accessible in developing countries. Therefore,
we studied the feasibility of a customized single nucleotide variant (SNV) microarray that
we developed to detect disease-causing variants and copy number variation (CNV) in
patients with PIDs for only 40 Euros.
Methods: Probes were custom-designed to genotype 9,415 variants of 277 PID-related
genes, and were added to the genome-wide Illumina Global Screening Array (GSA).
Data analysis of GSA was performed using Illumina GenomeStudio 2.0, Biodiscovery
Nexus 10.0, and R-3.4.4 software. Validation of genotype calling was performed by
comparing the GSA with whole-genome sequencing (WGS) data of 56 non-PID controls.
DNA samples of 95 clinically diagnosed PID patients, of which 60 patients (63%) had a
genetically established diagnosis (by Next-Generation Sequencing (NGS) PID panels or
Sanger sequencing), were analyzed to test the performance of the GSA. The additional
SNVs detected by GSA were validated by Sanger sequencing.
Results: Genotype calling of the customized array had an accuracy rate of 99.7%. The
sensitivity for detecting rare PID variants was high (87%). The single sample replication
in two runs was high (94.9%). The customized GSA was able to generate a genetic
diagnosis in 37 out of 95 patients (39%). These 37 patients included 29 patients in whom
the genetic variants were confirmed by conventional methods (26 patients by SNV and 3
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by CNV analysis), while in 8 patients a new genetic diagnosis was established (6 patients
by SNV and 2 patients suspected for leukemia by CNV analysis). Twenty-eight patients
could not be detected due to the limited coverage of the custom probes. However, the
diagnostic yield can potentially be increased when newly updated variants are added.
Conclusion: Our robust customized GSA seems to be a promising first-line rapid
screening tool for PIDs at an affordable price, which opens opportunities for low-cost
genetic testing in developing countries. The technique is scalable, allows numerous new
genetic variants to be added, and offers the potential for genetic testing not only in PIDs,
but also in many other genetic diseases.
Keywords: primary immunodeficiencies,microarray-based genotyping, SNPmicroarray, single nucleotide variants
(SNV) calling, copy number variants (CNV) calling
INTRODUCTION
Primary immunodeficiency disorders (PIDs) are a heterogeneous
group of diseases, including more than 400 distinct monogenic
inherited disorders, that affect the development and function
of the immune system (1–3). Obtaining a genetic diagnosis in
PID patients is crucial for providing an optimal standard of
care and personalized treatment tailored to specific molecular
defects (4). Current genetic diagnostic approaches for PIDs
are based on Sanger sequencing, next-generation sequencing
(NGS), and copy number variant (CNV) analysis. However, these
techniques are time-consuming, costly and involve complicated
data interpretation. Due to high costs and resource limitations,
not all genetic tests are available in developing countries;
therefore, rapid, robust, and inexpensive molecular tools must be
developed to meet this need.
Single nucleotide polymorphism (SNP) arrays are high-
throughput DNA microarrays that originated from the early
2000s and are a powerful platform for simultaneously analyzing
hundreds of thousands of SNPs and evaluating CNVs in a single
experiment (5). Recently, the cost of SNP arrays has decreased
substantially (from 300 Euro to 40 Euros per sample), driven
by the very large sample sizes needed to perform genome-
wide association studies (GWAS). Both Affymetrix/Thermofisher
and Illumina have designed cost-effective arrays that contain
∼800,000 variants, allowing a wide range of genetic variants to
be assessed.
Abbreviations: BRAF, v-raf murine sarcoma viral oncogene homolog B1; BTK,
bruton tyrosine kinase; CNV, copy number variants; CSF3R, colony stimulation
factor 3 receptor; CVID, common variable immunodeficiency; CXCR-4, C-X-
C chemokine receptor type 4; DCLRE1C, DNA cross-link repair protein 1C;
GATA2, gata-binding factor 2; GSA, global screening array; GWAS, genome-
wide association study; IKBKG, inhibitor of nuclear factor kappa B kinase
subunit gamma; INDELs, Insertions and Deletions; IUIS, the International Union
of Immunological Studies; LCSH, long-contiguous stretch of homozygosity;
LRBA, lipopolysaccharide (LPS)-responsive and beige-like anchor protein; NGS,
next-generation sequencing; PIDs, primary immunodeficiency disorders; SNP,
single nucleotide polymorphism; SNV, single nucleotide variants; STAT1, signal
transducer and activator of transcription 1; TNFRSF13B, tumor necrosis factor
receptor superfamily member 13B; TP53, tumor protein 53; VPS45, vacuolar
protein sorting 45 homolog; WAS; wiskott–aldrich syndrome; WGS, whole-
genome sequencing; XIAP, x-linked inhibitor of apoptosis protein.
To our knowledge, this “proof of principle study” is the
first to use the Illumina Global Screening Array (GSA; v1) to
detect rare Mendelian mutations, consisting of single nucleotide
variants (SNVs), small insertions and deletions (INDELs) and
CNVs, rather than SNPs. To the multi-ethnic genome-wide GSA
v1, we added 9,415 custom variants within the 277 validated
PID genes listed in the International Union of Immunological
Studies (IUIS) 2015 (6) to capture pathogenic variants. We then
analyzed 151 blood DNA samples derived from 95 patients
clinically diagnosed with PIDs and 56 non-PID controls that had
previously undergone whole-genome sequencing (WGS) at 80x
coverage, enabling the GSA results to be technically validated by
comparison with the WGS data.
MATERIALS AND METHODS
Array Design
The Illumina Custom GSA was produced as a research use-only
tool in San Diego, USA, ∼50,000 positions for a custom design.
Our array contained custom content representing all variants and
INDELs at the time of manufacture in the 277 PID-related genes
described by IUIS 2015 (6), derived from the licensed human
gene mutation database (HGMD) professional (7). Of the 10,250
variants selected, 9,415 (91.9%) were successfully placed on the
array by Illumina. The aim of this custom part of the array was
to identify the known PID variants by calling SNVs and CNVs in
these PID genes. In addition, the Illumina GSA contains a multi-
ethnic genome-wide backbone of SNPs with 696,375 probes,
which enables genome-wide CNV calling.
Sample Selection and DNA Preparation
On the first run, a total of 95 patients clinically diagnosed with
PIDs from the Erasmus Medical Center PID Biobank/Clinical
Repository were randomly selected to test the performance of
the array to diagnose PIDs. A detailed description of the PID
patients is shown in Supplementary (Tables S1, S2). All patients
had undergone conventional genetic testing by either targeted
NGS PID panel or Sanger sequencing based on their clinical
phenotype. Seventy-one SNVs and/or small INDELs and four
exon deletions including 3 homozygous exon deletions and
1 hemizygous deletion were discovered. A genetic diagnosis
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was established in 60 of the 95 patients (63%). The remaining
35 patients were unresolved, indicating the possibility of an
uncharacterized genetic variant. In 7 of these 35 patients, some
variants were discovered (patient no. 1–7, Table S2); however,
these were not found to be sufficient enough to account for the
clinical phenotype based on the inheritance pattern of the disease.
A single sample of a healthy individual that had undergone
WGS sequencing was added on the first run for array validation
(HapMap NA 19240). DNA was extracted from blood using a
DNA Isolation Kit (Qiagen, Valencia, CA, USA). On the second
run of the array, DNA samples of 41 PID patients (that were
also included in the first run) and 55 non-PID controls which
had pre-existing WGS data were selected. All samples were
registered by the biobanking and biomolecular resources research
infrastructure (BBMRI) and/or consent for molecular diagnostic
testing according to the Helsinki Guidelines.
Validation of Array-Based Genotyping
For validation of the genotype calling of the customized array,
we used one HapMap sample, which has been investigated to
benchmark various WGS platforms at the Erasmus University
Medical Center (8) and 55 samples with pre-existing WGS data
reaching an average depth of 80x. These samples were originated
from unrelated parents of a genetic study of craniofacial
malformations (9). For these 56 non-PID samples that previously
had undergone WGS, SNV position genotypes of the custom
probes were called from the BAM files, using SAMtools/
BCFtools (Li, 2011), and were compared to the genotype called
from the array for the same sample. Probes with different
callings between the array and the WGS for these 56 control
samples were excluded from analysis because of the possibility
of probe malfunction.
Genetic Data Analysis
Array Quality Control
Two IDAT files (green, red) were generated per sample and
uploaded on to Illumina GenomeStudio 2.0 software prior to
quality control (QC) analysis using PLINK (v1.9) (10). QC
analysis tested for genotyping efficiency per SNP at a threshold
of 97.5%, with the sample call rate set at 97.5% and deviations
from Hardy-Weinberg equilibrium defined as P < 1 × 10−4.
Additionally, zCall was performed to improve rare variant calling
(11), after which a stringent SNP and sample call rate filter of 98%
was applied. Ethnic origin and sex/gender were used to control
for data integrity during sample processing and analysis.
SNV Calling
Detailed variant analysis for SNV detection was performed
on post-QC data using PLINK (v1.9), GenomeStudio 2.0, and
R-3.4.4. Only disease-causing variants according to HGMD
classifications were selected. Next, variants were filtered against
the gnomAD database with a frequency threshold of below
0.5 %. Variants that occurred more than once in the dataset
were excluded as controls for the effect of faulty probes, while
all X-linked heterozygous calls in males were excluded, these
would lead likely to false-positive results. Lastly, all remaining
variants were manually checked using genotyping module SNP
graphs generated by GenomeStudio 2.0 to determine whether
the genotype call matched the expected genotype by their signal
intensity, if not the variant was excluded.
CNV Calling
CNV analysis was carried out using the SNP-FASST2
Segmentation Algorithm within BioDiscovery Nexus Copy
Number Discovery Version 10.0 (El Segundo, USA). Large
chromosomal aberrations were visually identified by making
log-ratio and B-allele frequency plots in order to detect
deletions, amplifications, polyploidy or long-contiguous stretch
of homozygosity (LCSH). For small CNVs, the significance
threshold for CNV calling within Nexus 10.0 was set at 5× 10−6
requiring a minimum of 4 probes per segment and a maximum
contiguous probe spacing of 1,000 Kbp. Log2 ratio values of
−0.3 and −1.1 were used to detect single and more than two
copy losses, respectively, while values of 0.2 and 0.7 were used
to detect single and more than two copy gains. Only CNVs, that
were located in the 277 PID according to the IUIS classification
genes were selected. Next, these CNVs were filtered against the
Nexus database for known CNVs. For heterozygous CNVs, the
overlap with known CNVs was set to 0%, whereas no threshold
was used for homozygous CNVs. Lastly, a frequency filter was
applied such that only CNVs occurring once in the dataset were
selected to filter any CNVs that arose due to probe malfunction
when capturing CNVs.
Validation by Sanger Sequencing and Calculation of
Diagnostic Yields
Sanger sequencing was performed to validate all newly detected
SNVs. The sensitivity (of previously known variants) and the
overall sensitivity (including the addition of newly detected
“Sanger confirmed” variants) was defined as the proportion of
SNVs and CNVs that could be replicated in both techniques. The
diagnostic yield was calculated at the level of patients when a
genetic diagnosis could be made. Reaching a conclusive genetic
diagnosis is based on identifying a genetic variant with an
inheritance pattern that matches the inheritance pattern reported
in the Online Mendelian Inheritance in Man (OMIM) database,
on observing close correlation with the clinical PID phenotypes,
and/or on mentioning of the variant in the IUIS database.
Assessment of the Reproducibility
To assess the reproducibility of the array, we focused only on
the custom content of the GSA and compared the post-QC
data for the 41 overlapping PID samples in the two array runs.
The genotypes acquired in the two runs were compared for the
same sample.
RESULTS
Overall Technical Array Performance
We performed two array genotyping experiments, where DNA
samples were on the array (run 1 and run 2) to allow inter-assay
comparison. Of the 9,415 custom variants added to the standard
GSA v1 content, 8,883 and 8,852 variants were included in the
post-QC data of the custom content for the first and second
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runs, respectively. In the second run, 3 samples (2 PID and 1
non-PID) were excluded from further analysis as they failed to
achieve the sample call rate threshold of 98%, leaving 39 PID
samples for inter-assay validation and, 55 samples from non-PID
healthy controls (in whomWGS was performed) for comparison
of the array genotype calling with WGS genotype callings. The
correlation between the genotype of the custom SNVs in the
PID array and WGS data of the 55 non-PIDs was robust. Of the
8,852 post-QC variants in the second run, 1,902 probes captured
small (INDELs) and 6,950 probes captured SNVs. These 6,950
variants were subsequentially checked against the WGS data
(of all non-PID controls) and genotyping of 6,928 (99.7%) of
the variants on the custom GSA v1 matched that acquired by
WGS (at 80x coverage). Subsequently, we checked all the non-
reference genotype SNV calls made by the GSA (n = 2,626) as
these would be identified as positive results and observed that
only 11 (0.15%) did not match the genotype called by WGS.
Moreover, these 2,626 calls were almost exclusively reported as
benign variants/polymorphisms in HGMD.
SNV Analysis in PID Patients
We then analyzed the array-based genetic diagnosis in 95
patients with clinically diagnosed PIDs. Our customized GSA
v1 detected 80 SNVs or small INDELs, of which 30 variants
were originally detected by conventional methods (Figure 2 and
Table S3). The diagnosis was confirmed in 26 out of 60 patients
who had a previously established genetic diagnosis (Table S1).
In 31 patients, the array could not replicate the genetic variants
found by conventional diagnostics. Seven of these 31 patients had
variants that could have been measured by the specific probes on
the array, but the GSA failed to do so, because these probes did
not pass the stringent QC after rare-variant calling performed
with zCall. For 2 of these 31 patients, the GSA was only able
to identify 1 of 2 variants as these patients were compound
heterozygous. For the remaining 21 patients (29 variants as some
patients had multiple variants), the GSA could not replicate the
SNV and/or INDEL as the variants were not known at the time of
GSA manufacturing process and therefore no probes were added
to the array to investigate these variants.
Interestingly, in 35 patients whom conventional diagnostics
did not find a causative genetic variant (Table S2), our
customized GSA could detect pathogenic variants and lead to
a diagnosis in 6 patients. These variants included heterozygous
variants in signal transducer and activator of transcription 1
(STAT1), colony stimulation factor 3 receptor (CSF3R), tumor
necrosis factor receptor superfamily member 13B (TNFRSF13B),
inhibitor of nuclear factor-kappa B kinase subunit gamma
(IKBKG), C-X-C chemokine receptor type 4 (CXCR-4), and a
homozygous mutation in vacuolar protein sorting 45 homolog
(VPS45). These genes were not analyzed as the potential
genetic cause during conventional diagnostics, possibly due to
overlapping clinical phenotypes of the patients. In 7 patients
some heterozygous variants were previously detected (patient no.
1–7,Table S2), the variants could be reproduced in 2 patients. For
the other 5 patients, GSA could not replicate the results found
from the conventional methods as the probes were not added
on the array. A newly updated version of the GSA is expected
to allow all these SNVs to be assessed in more detail and reveal
how well they can be detected.
Next, we set out to validate the observed causal variants
newly found by GSA with Sanger sequencing (n = 46). For 5
variants in 3 samples, Sanger sequencing could not be performed
because of lack of available DNA. For the remaining 41 variants,
Sanger sequencing could confirm 38 out of 41 variants (92.7%)
demonstrating a high validation rate between GSA and Sanger
sequencing, although some variants yielded a different nucleotide
change at a slightly different position from the investigated
position with the array (n= 8).
CNV Analysis
The genome-wide CNV analysis detected large inter- and
intragenic regions of LCSH suggesting consanguinity in 39
PID samples (Table S1 and Figure 1B). In 12 PID patients,
CNV analysis based on the array genotyping data could reveal
large chromosomal aberrations and microdeletions at the gene
level. Three of the previously known exon deletions that were
discovered during conventional diagnostics could be reproduced,
including 2 patients with a homozygous DNA cross-link repair
protein 1C (DCLRE1C) deletion (Figure 1A) and 1 patient with
a hemizygous x-linked inhibitor of apoptosis protein (XIAP)
deletion (patient no. 3,6,27 in Table S1). One patient with an
established homozygous loss of immunoglobin heavy constant
mu (IGHM) could not be replicated by the GSA during CNV
analysis (patient no. 34 inTable S1). Both SNV and CNV analysis
detected genetic variants in one patient with a mutation in SH2
Domain Containing 1A (SH2D1A) (patient no. 13 in Table S1).
Interestingly, 2 PID patients without a previous genetic
diagnosis were recognized as having monosomy 7, which is
suspected for a hematologic malignancy rather than PID (patient
no. 4,8 in Table S2). In another patient, we identified (in a single
GSA experiment) both trisomy 8 (by CNV analysis) as well as a
GATA-binding factor 2 (GATA2) variant (by SNV calling; patient
no. 26 in Table S1 and Figures 1C,D), which is suggestive for a
secondary hematologic malignancy in this patient.
Sensitivity Based on Variants and
Diagnostic Yield at the Patient Level
In this proof of principle study, the customized GSA array could
replicate 30 out of 71 previously detected SNVs. However, 34
variants could not be investigated due to limited coverage of
probes at the time of GSA design; and, 3 of the 4 previously
detected CNVs could also be replicated. The sensitivity for
identifying the known genetic variants (SNVs and CNVs) that
the GSA can detect compared to conventional methods was
80% (33/41). Sanger sequencing could confirm 38 out of 46
newly found SNVs by GSA, although 5 variants could not be
investigated due to a lack of DNA in 3 patients. The overall
sensitivity including the addition of these newly found variants
that underwent Sanger sequencing was 71/82 (87%) (Table S3).
At the patient level, we were able to establish a genetic
diagnosis using the GSA technology in 37 out of 95 PID
patients (39%). These 37 patients included 29 patients in whom
conventional methods had previously detected genetic variants
(26 patients by SNV and 3 by CNV analysis), but also 8 newly
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FIGURE 1 | (A) Log-ratio plot, which shows the amount of DNA per probe (normal is two copies) and B-allele frequency plot that shows the genotype for a probe
(normal is AA/AB/BB). The log-ratio plot shows a homozygous deletion depicted by the light red area in DCLRE1C (Artemis) deletion detected by CNV analysis. The
call was based on 40 consecutive probes having intensity values below the threshold; (B) The presence of multiple regions of long-contiguous stretch of homozygosity
(LCSH) in the B-allele frequency plot is suggesting consanguinity (red arrows); In a single experiment, the customized PID Global Screening Array (GSA) array identified
(C) a trisomy 8 (blue box) seen in the log-ratio plot by amplification of DNA and seen in the B-allele frequency plot by polyploidy (AAA/AAB/ABB/BBB) by CNV
(Continued)
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FIGURE 1 | calling along with (D) a GATA2 mutation (green arrow) by SNV calling suggesting a secondary malignancy in the patient; (E) The customized GSA array
comprising 9,415 PID related variants/ INDELs and a multi-ethnic genome-wide backbone on the entire array adds up to 696,375 probes; (F) A CSF3R mutation
detected by SNV analysis (green arrow) was confirmed by Sanger sequencing. CNV, copy number variants; CSF3R, colony stimulation factor 3 receptor; DCLRE1C,
DNA cross-link repair protein 1C; GATA2, gata-binding factor 2; GSA, Global Screening Array; Sanger, Sanger sequencing; INDELs, Insertions and Deletions; PIDs:
primary immunodeficiency disorders, SNV: single nucleotide variants.
FIGURE 2 | Flow chart describing the numbers of variants identified by GSA array compared to conventional methods in 95 clinically diagnosed PID patients in the
first run. CNV, copy number variants; DCLRE1C: GSA, Global Screening Array; PCR, Sanger sequencing; NGS, next-sequencing sequence; PID, Primary
immunodeficiency disorder; SNV, single nucleotide variants.
suspected patients (6 by SNV and 2 patients suspected from
leukemia as detected by CNV analysis). In 28 patients (that had
established variants with conventional techniques) the variants
could not be replicated by GSA due to the sparse coverage of
the custom probes at the time that the array was designed and
therefore these patients could not obtain a conclusive genetic
diagnosis. In 20 PID patients, neither conventional nor GSA
testing were able to obtain a conclusive genetic diagnosis. The
detected variants leading to the diagnosis and numbers of
patients in whom a diagnosis was made, comparing between
conventional methods and GSA is shown in (Figure 2 and
Table S3).
Reproducibility
As indicated above, 39 PID samples could be investigated
for inter-assay validation in the second run. Our results
demonstrated that for 37 out of 39 patients, the genetically causal
variants from the first run could be replicated in the second run
(94.9%) (Tables S1, S2). Large CNVs such as large chromosomal
aberrations were replicated; however, small heterozygous exon
deletions did not replicate well (probably due to short primer
length of the custom probes). Finally, we compared all post-QC
data for the custom variants from the first run with the data
generated from the second run for these 39 patients (8,883 and
8,852 variants respectively). There was overlap between 8,541
variants and we found only 13 (0.22%) differences between the
genotype calls in the two runs.
Costs
The costs for NGS in one patient including analysis in a clinical
diagnostic setting is about 1,000 Euros. However, the costs
depend strongly on the national economic system and the local
health care infrastructure. The net price forWESwithout analysis
and overhead varies from 350 to 600 Euros. GSA, however, can
be performed for <10% of the WES price. With our effort, we
performed the PID array test for the affordable price of about
40 Euros per sample. In this study, we were able to diagnose
roughly 40% of patients by the array. Given a GSA cost of
€40 per sample, initial costs for 100 patients is €4,000. The 60
remaining undiagnosed samples will undergo NGS or targeted
gene panel sequencing assuming €1,000 per sample. Total costs
for this scenario will be roughly €64,000. On the other hand,
if we use directly NGS or targeted gene panel sequencing, the
costs will be €100,000. For both NGS and GSA techniques,
we perform Sanger sequencing for confirmation. So, by using
GSA as a screening tool in PID diagnostics we can save about
36,000 Euros per 100 patients. This makes the diagnostic array
an affordable promising candidate for initial screening analysis in
the standard-of-care, in particular in developing countries, where
genetic testing is not yet available.
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DISCUSSION
A high-throughput, rapid and inexpensive tool is required for
identifying underlying genetic defects in a clinical care setting,
especially in low-income countries. SNP array technology is a
powerful genomic analysis tool which has been widely used
at the population level, but not for detecting rare pathogenic
SNV variants.
In this study, we present a comprehensive diagnostic SNP
array that is able to screen at a genome-wide level, including rare
PID gene variants. This method possesses potential advantages as
compared to conventional targeted gene panel NGS diagnostics.
As an initial screening test, the customized PID array had a high
sensitivity (87%) for capturing rare mutations and had a strong
reproducibility (0.22% difference in genotype callings between
two runs). Moreover, we observed a high validation accuracy
compared to NGS data (0.16% difference in genotype callings).
This is different from a recent previous study, which found a
very low association between array and NGS data (12). However,
there are important differences between the two studies. Firstly,
their study used an Affymetrix/ Thermofisher product while
ours used Illumina technology. SNP calling is based on different
algorithms in these two platforms and thus might influence
variant calling, particularly for rare variants. Secondly, we used
the zCall algorithm to enhance rare variant calling, results in
better genotype calling for this class of variants. A large number
of newly found variants could also be reproduced by Sanger
sequencing. However, there was some disagreement regarding
the precise nucleotide change (n=8).Most likely, this is due to the
hybridization of the probe when a variant (in the near vicinity) is
present. This emphasizes the need for close investigation of the
specific region with Sanger sequencing and further research on
the quality of calling of individual probes.
Certainly, there is a clear trend toward implementing NGS in
academic institutions for genetic diagnostics; however, there is
also a trend toward array genotyping, particularly in direct-to-
consumer companies. The basic cost price is 10-fold higher for
NGS as compared to GSA arrays. NGS outputs a large quantity
of data with concomitant much higher costs for storage and
analysis. The overall price including analysis and overhead will
be significantly higher for NGS than GSA. The price for NGS is
expected to remain high over the next 5 years, therefore NGS will
remain unaffordable in developing countries. Although NGS will
still be necessary to detect novel variants, most NGS approaches
for PID reported a diagnostic yield from 15 to 79%within amixed
PID population (13), with a diagnostic yield with our customized
GSA of 39% falling within this range. A limitation of current NGS
diagnostic approaches is that unless the DNA is sequenced with
appropriate depth, NGS technology cannot accurately capture
CNVs. Detection of CNVs increases the diagnostic yield by an
average of 4.2% (13). Furthermore, there is no consensus about
the interpretation of the variants revealed by NGS, whereas the
interpretation of GSA output is simpler since the investigated
variants are known beforehand.
The GSA has several clear advantages. The average turn-
around-time for GSA is 1 week, therefore our economic and
rapid customized PID array represents an ideal approach to
broadly detecting known pathogenic variants in a primary
screen, which can be followed by further NGS analysis when
no genetic diagnosis can be made. Since the GSA was designed
to simultaneously capture both SNVs and CNVs in a single
experiment, it may also indicate secondary malignancies in
at-risk PID patients. This is illustrated in our study by the
co-occurrence of a GATA2 variant and a CNV aberration
of chromosome 8, which is indicative for acute myeloblastic
leukemia (14). Due to the complexity and variety of clinical
presentations, hematological malignancies can be misdiagnosed
as a PID. We also detected excessive LCSH in some of our
patients, which is clearly indicating consanguinity. Such LCSH
areas are likely to reflect the origin of recessive diseases, such
as imprinting disorders, triploidy and duplications in which the
pathogenic mutations are located (4). Although not observed
in this study, 22q11 microdeletion syndrome (4) and IL-25
hyperdiploidy can be discovered by CNV analysis (15). SNVs
related to inflammatory and autoimmune complications in
common variable immunodeficiency (CVID) were reported (16).
SNV analysis is also capable of detecting a Uniparental Disomy
as shown recently in a patient with lipopolysaccharide (LPS)-
responsive and beige-like anchor protein (LRBA) Deficiency (17).
Finally, enriched GSA with hotspot mutations enable the
screening for other immune-mediated diseases such as Blau
syndrome (NOD2), mastocytosis (KIT), and as cancer driver
mutations in proto-oncogenes such as v-raf murine sarcoma viral
oncogene homolog B1 (BRAF) or tumor suppressor genes such
as tumor protein 53 (TP53). Therefore, a similar approach of
an enriched array with known pathogenic variants may be a
promising screening tool for other genetic diseases. Although it
is unlikely that the array will work better for one disease than
another, trials should be performed to conclusively demonstrate
the utility of arrays for detecting rare disease-causing genetic
variants in a range of genetic disorders.
Despite its advantages, this customized array has some
limitations. Firstly, it is unable to detect novel SNV, i.e., those that
have not yet been reported in literature and/or databases, it can
only detect variants that are included on the array. However, since
GSA is scalable, it is possible to increase the number of variants
in additional genes. The current version of our customized
array contained only selected variants of 277 PID-causing genes
derived from the IUIS 2015 classification (as published at the time
the array was designed). The total number of known PID genes
has now vastly increased, with 420 inborn errors of immunity
as described in the updated IUIS 2019 classification (3). By
updating the GSA with newly found variants, the diagnostic
yield is expected to improve significantly. This warrants for
further assessment of the GSA as a primary screening tool.
Although we cannot test every probe by validation with known
carriers and cannot guarantee for possible probe malfunction,
we expect no technical reasons (given the high accuracy rate
compared with NGS and the high validation rate compared
with Sanger sequencing) why the sensitivity and diagnostic yield
should not increase accordingly. Indeed, it should be possible
to create a user-friendly, automated platform that analyzes data
efficiently, thus benefiting medical decision making in patients
with PIDs.
In conclusion, this robust customized array is a promising
first-line rapid screening tool for PID and probably other
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genetic diseases at an affordable cost. This method provides new
perspectives for genetic testing in developing countries where
PIDs are currently under-diagnosed.
DATA AVAILABILITY STATEMENT
The datasets for this article are not publicly available because
of the legal and ethical restrictions, as this will compromise the
anonymity of the participants in the study, according to the
GDPR related restrictions.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved byMRECErasmusMedical Center Rotterdam.Written
informed consent to participate in this study was provided by the
participants’ legal guardian/next of kin.
AUTHOR CONTRIBUTIONS
NS and RW contributed equally to this work through writing
the manuscript, data collection, and data analysis. LB, JM,
and AU performed data analysis and wrote the manuscript.
LX, BB, MB, and WD wrote the manuscript and supported
the clinical data. SS, JG, IM, VD, KS, PC, and JD wrote the
manuscript. AL and KH performed Sanger sequencing and wrote
the manuscript. PS and PH wrote the manuscript and took
overall control of this work. The SEAPID Consortium Members
were involved in the conceptual design of the study and writing
the manuscript.
FUNDING
This study was supported by Internal funding of Department
of Internal Medicine, Department of Pathology & Clinical
Bioinformatics, Erasmus Medical Center, Rotterdam, the
Netherlands and grant from H2020 ImmuneAID, Bigmedilytics,
Moodstratification, and TranSYS.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.00614/full#supplementary-material
REFERENCES
1. Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al.
The 2017 IUIS phenotypic classification for primary immunodeficiencies. J
Clin Immunol. (2018) 38:129–43. doi: 10.1007/s10875-017-0465-8
2. Picard C, Gaspar HB, Al-Herz W, Bousfiha A, Casanova J-L, Chatila
T, et al. International union of immunological societies: 2017 primary
immunodeficiency diseases committee report on inborn errors of immunity. J
Clin. Immunol. (2018) 38:96–128. doi: 10.1007/s10875-017-0464-9
3. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-
Rundles C, Etzioni A, et al. Human inborn errors of immunity:
2019 update on the classification from the international union of
immunological societies expert committee. J Clin Immunol. (2020)
40:24–64. doi: 10.1007/s10875-019-00737-x
4. Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan
Y, et al. Use of genetic testing for primary immunodeficiency patients. J Clin
Immunol. (2018) 38:320–9. doi: 10.1007/s10875-018-0489-8
5. Louhelainen J. SNP arrays. Microarrays. (2016):5:27. doi: 10.3390/micro
arrays5040027
6. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, et al. The
2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin
Immunol. (2015) 35:727–38. doi: 10.1007/s10875-015-0198-5
7. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S,
et al. The human gene mutation database: towards a comprehensive
repository of inherited mutation data for medical research, genetic diagnosis
and next-generation sequencing studies. Hum Genet. (2017) 136:665–
77. doi: 10.1007/s00439-017-1779-6
8. Stubbs A, McClellan EA, Horsman S, Hiltemann SD, Palli I, Nouwens S,
et al. Huvariome: a web server resource of whole genome next-generation
sequencing allelic frequencies to aid in pathological candidate gene selection.
J Clin Bioinforma. (2012) 2:19. doi: 10.1186/2043-9113-2-19
9. Florisson JM, Verkerk AJ, Huigh D, Hoogeboom AJM, Swagemakers S,
Kremer A, et al. Boston type craniosynostosis: report of a second mutation
in MSX2. Am J Med Genet A. (2013) 161:2626–33. doi: 10.1002/ajmg.a.36126
10. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet. (2007) 81:559–75. doi: 10.1086/519795
11. Goldstein JI, Crenshaw A, Carey J, Grant GB, Maguire J, Fromer
M, et al. zCall: a rare variant caller for array-based genotyping:
genetics and population analysis. Bioinformatics. (2012) 28:2543–5.
doi: 10.1093/bioinformatics/bts479
12. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q,
et al. Variant across 141,456 human exomes and genome reveals the spectrum
of loss-of-function intolerance across human protein-coding genes. BioRxiv.
(2019) 531210. doi: 10.1101/531210
13. Yska HAF, Elsink K, Kuijpers TW, Frederix GWJ, van Gijn ME, van
Montfrans JM. Diagnostic yield of next generation sequencing in genetically
undiagnosed patients with primary immunodeficiencies: a systematic review.
J Clin Immunol. (2019) 39:577–91. doi: 10.1007/s10875-019-00656-x
14. Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and
related myeloid neoplasms. Semin Hematol. (2017) 54:81–6.
doi: 10.1053/j.seminhematol.2017.05.002
15. Green M, Camilleri E, Gandhi MK, Peake J, Griffiths LR. A novel
immunodeficiency disorder characterized by genetic amplification of
interleukin 25. Gene Immun. (2011) 12:663. doi: 10.1038/gene.2011.50
16. Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B,
et al. Genome-wide association identifies diverse causes of common
variable immunodeficiency. J Allergy Clin Immunol. (2011) 127:1360–7.
e1366. doi: 10.1016/j.jaci.2011.02.039
17. Soler-Palacin P, Garcia-Prat M, Martin-Nalda A, Franco-Jarava C, Riviere JG,
Plaja A, et al. LRBA deficiency in a patient with a novel homozygous mutation
due to chromosome 4 segmental uniparental isodisomy. Front Immunol.
(2018) 9:2397. doi: 10.3389/fimmu.2018.02397
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Suratannon, van Wijck, Broer, Xue, van Meurs, Barendregt,
van der Burg, Dik, Chatchatee, Langerak, Swagemakers, Goos, Mathijssen, Dalm,
Suphapeetiporn, Heezen, Drabwell, Uitterlinden, van der Spek, van Hagen and the
South East Asia Primary Immunodeficiencies (SEAPID) Consortium. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Immunology | www.frontiersin.org 8 April 2020 | Volume 11 | Article 614
